IL17RD抗体—艾普蒂

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane 1-2: A172 and 231 cell lysates, Primary antibody: P07049(IL17RD Antibody) at dilution 1/900, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 5 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P07049(IL17RD Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

IL17RD (Interleukin-17 Receptor D), also known as Sef (similar expression to fibroblast growth factor genes), is a transmembrane protein that belongs to the IL-17 receptor (IL-17R) family. Initially identified for its homology to fibroblast growth factor receptors (FGFRs), IL17RD functions as a dual regulator in both IL-17 and FGF signaling pathways. It acts as a feedback inhibitor, modulating downstream signaling by interacting with IL-17RA or FGFR1 to suppress NF-κB, MAPK, or other pathways, thereby influencing inflammatory responses, cell differentiation, and tissue homeostasis. Dysregulation of IL17RD has been implicated in autoimmune diseases, cancer, and developmental disorders.

Antibodies targeting IL17RD are essential tools for studying its expression, localization, and molecular interactions. These antibodies are commonly used in techniques such as Western blotting, immunohistochemistry, and flow cytometry to detect IL17RD in cell lines, tissues, or disease models. Some antibodies are designed to recognize specific epitopes, enabling the investigation of post-translational modifications or functional domains. Research utilizing IL17RD antibodies has revealed its tissue-specific expression patterns, reduced levels in certain cancers (e.g., prostate, breast), and regulatory roles in autoimmune conditions like psoriasis or rheumatoid arthritis. Additionally, therapeutic antibodies targeting IL17RD are being explored to modulate inflammatory pathways or disrupt oncogenic signaling networks, highlighting its potential as a biomarker or drug target.